Menu

Press Releases

CVS Health Research Institute Study Finds Newly Diagnosed Diabetes Patients Less Likely to Need Treatment Intensification When Started on a Generic Drug

,

WOONSOCKET, R.I., Oct. 31, 2014 /PRNewswire/ –New research from CVS Health (NYSE: CVS) finds starting a new diabetes patient on metformin, a generic oral diabetes medicine that helps control blood sugar levels, reduced the need to add on additional treatments to control the condition over time. Although there are many classes of oral diabetes medications, […]

GE Healthcare launches startup campus Health Innovation Village to help entrepreneurs speed up health tech solutions

,

Helsinki, Finland – October 28, 2014 – Today GE Healthcare officially opens Health Innovation Village, its first health tech startup campus, at its Finnish headquarters with the Minister of Economic Affairs in Finland, Jan Vapaavuori and the Mayor of Helsinki, Jussi Pajunen. The Health Innovation Village saw its first inhabitants move in this summer. Today, […]

SpendWell Partners with One of the Largest Vision Networks in the US

,

Davis Vision’s providers gain access to new group of direct-pay patients PORTLAND, OCTOBER 27, 2014 — SpendWell HealthTM, an online marketplace for health care services, has signed an agreement with Davis Vision, one of the nation’s largest eye care provider networks with more than 44,000 providers and over 19 million members. Through the partnership, optometrists, […]

Merck Receives FDA Breakthrough Therapy Designation for KEYTRUDA® (pembrolizumab) in Advanced Non-Small Cell Lung Cancer

, ,

October 27, 2014 – WHITEHOUSE STATION, N.J.–(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, for the treatment of patients with Epidermal Growth Factor Receptor (EGFR) mutation-negative, and Anaplastic Lymphoma […]

Alexion Launches Every Day with HPP™ Campaign in Support of Hypophosphatasia (HPP) Awareness Week

,

Campaign highlights unique stories and experiences of the HPP community to raise awareness CHESHIRE, Conn. October 27, 2014 –(BUSINESS WIRE)–Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced the launch of the Every Day with HPP™ campaign in support of the third annual Hypophosphatasia (HPP) Awareness Week Oct. 26–Nov. 1, 2014. HPP Awareness Week is a national public […]

Novartis announces divestiture of influenza vaccines business to CSL for USD 275 million

,

CSL to acquire Novartis influenza vaccines business, including development pipeline, for USD 275 million Announcement follows a transaction announced on April 22, 2014 to divest the non-influenza segments of Novartis Vaccines to GlaxoSmithKline Basel, Switzerland, October 26, 2014 – Novartis today announced it has entered into a definitive agreement to divest its influenza vaccines business […]

GE Healthcare Life Sciences wins prestigious bioprocessing industry award

,

CHALFONT ST. GILES, UK – 24 October 2014 – GE Healthcare Life Sciences (NYSE:GE) has won a BioProcess International (BPI) industry award for excellence in bioprocessing facility design. The BPI awards, voted for by bioprocess experts and hosted by industry publication BioProcess International, recognize outstanding products, services, partnerships and people that have had the greatest […]

CHMP recommends label update for Esbriet in idiopathic pulmonary fibrosis, strengthening mortality benefit and reinforcing safety profile

, ,

Pooled analysis of ASCEND and two CAPACITY phase III trials show 48 percent reduction in mortality risk at one year1 ASCEND data reinforces the Esbriet safety and efficacy profile1 Approximately 110,000 people in Europe have idiopathic pulmonary fibrosis (IPF), an irreversible, progressive, fatal lung disease2- 5 Only 20–40 percent of IPF patients survive five years […]

Researchers to Present Data on Soliris® (eculizumab) as a Treatment for Patients with aHUS at ASN 2014 Annual Meeting

,

CHESHIRE, Conn. October 23, 2014 –(BUSINESS WIRE)–Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that researchers will present seven posters detailing findings from clinical studies of Soliris® (eculizumab) in patients with atypical hemolytic uremic syndrome (aHUS) as well as from the Global aHUS Registry at the annual meeting of the American Society of Nephrology (ASN), being held November […]

Roche invests for the future in its Basel site

,

Investments of 3 billion Swiss francs in modern research infrastructure, attractive workplaces and sustainable site development Basel, 22 October 2014 – Today Roche presented development plans for its Basel site. Over the next 10 years, Roche will invest 3 billion Swiss francs in the construction of a new research and development centre for around 1,900 employees, […]

«‹ 16 17 18 19›»